Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
Back to Home
V

VCYT

Nasdaq

VERACYTE, INC.

Latest disclosureSeptember 22, 2026
Insider score Why 0?
0/ 100
Qualifying buys · 30d
$0

0 purchases · 21 sales

Price by TradingViewDelayed quote from TradingView, for viewing only. It does not power Whale Atlas scores or alerts. If the quote does not load, open the TradingView link.

Insider transactions 46

Limited filing history
All46Buying0Selling21Other25
Filters

Last 30 daysNo qualifying insider buying. Sales: $365.35K by 2 insiders.

21 of 46 trades · April 10, 2026 – September 21, 2026Incomplete history: this shows the filings imported so far, not every filing ever made. Dates are trade dates. Filters affect this table only.

Showing the first 6 of 20 trades on this page.

Sale disclosed

John Leite

Global Chief Commercial Off

Common Stock

Reported value
$160.6K
Reported price
$40.00 / share
Traded September 21, 2026Filed September 22, 2026SEC filing
Sale disclosed

Jens Holstein

Director

Common Stock

Reported value
$204.75K
Reported price
$40.9494 / share
Traded September 14, 2026Filed September 16, 2026SEC filing
Sale disclosed

Phillip G. Febbo

Chief Scientific & Med Officer

Common Stock

Reported value
$446.3K
Reported price
$42.8933 / share
Traded September 4, 2026Filed September 4, 2026SEC filing
Sale disclosed

Phillip G. Febbo

Chief Scientific & Med Officer

Common Stock

Reported value
$118.11K
Reported price
$43.6618 / share
Traded September 4, 2026Filed September 4, 2026SEC filing
Sale disclosed

Rebecca Chambers

Chief Financial Officer

Common Stock

Reported value
$106.03K
Reported price
$42.8059 / share
Traded September 4, 2026Filed September 4, 2026SEC filing
Sale disclosed

Rebecca Chambers

Chief Financial Officer

Common Stock

Reported value
$51.36K
Reported price
$43.714 / share
Traded September 4, 2026Filed September 4, 2026SEC filing
Sale disclosed

Annie McGuire

EVP, General Counsel

Common Stock

Reported value
$92.17K
Reported price
$42.7916 / share
Traded September 4, 2026Filed September 4, 2026SEC filing
Sale disclosed

Annie McGuire

EVP, General Counsel

Common Stock

Reported value
$48.04K
Reported price
$43.6718 / share
Traded September 4, 2026Filed September 4, 2026SEC filing
Sale disclosed

Muna Bhanji

Director

Common Stock

Reported value
$80.1K
Reported price
$42.97 / share
Traded September 1, 2026Filed September 3, 2026SEC filing
Sale disclosed

Karin Eastham

Director

Common Stock

Reported value
$168.91K
Reported price
$52.7832 / share
Traded June 18, 2026Filed June 22, 2026SEC filing
Sale disclosed

Karin Eastham

Director

Common Stock

Reported value
$28.33K
Reported price
$53.5504 / share
Traded June 18, 2026Filed June 22, 2026SEC filing
Sale disclosed

Annie McGuire

EVP, General Counsel

Common Stock

Reported value
$69.03K
Reported price
$49.3061 / share
Traded June 4, 2026Filed June 4, 2026SEC filing
Sale disclosed

Annie McGuire

EVP, General Counsel

Common Stock

Reported value
$89.01K
Reported price
$50.1168 / share
Traded June 4, 2026Filed June 4, 2026SEC filing
Sale disclosed

Rebecca Chambers

Chief Financial Officer

Common Stock

Reported value
$78.85K
Reported price
$49.2836 / share
Traded June 4, 2026Filed June 4, 2026SEC filing
Sale disclosed

Rebecca Chambers

Chief Financial Officer

Common Stock

Reported value
$98.23K
Reported price
$50.0913 / share
Traded June 4, 2026Filed June 4, 2026SEC filing
Sale disclosed

Marc Stapley

Chief Executive Officer

Common Stock

Reported value
$6.92M
Reported price
$50.1234 / share
Traded June 4, 2026Filed June 4, 2026SEC filing
Sale disclosed

John Leite

Global Chief Commercial Off

Common Stock

Reported value
$699.73K
Reported price
$50.0703 / share
Traded June 4, 2026Filed June 4, 2026SEC filing
Sale disclosed

Jonathan Wygant

VP, Chief Accounting Officer

Common Stock

Reported value
$1.09M
Reported price
$45.401 / share
Traded May 22, 2026Filed May 27, 2026SEC filing
Sale disclosed

Robert S. Epstein

Director

Common Stock

Reported value
$440.13K
Reported price
$44.0129 / share
Traded May 20, 2026Filed May 22, 2026SEC filing
Sale disclosed

Annie McGuire

SVP, General Counsel

Common Stock

Reported value
$194.13K
Reported price
$38.05 / share
Traded May 6, 2026Filed May 8, 2026SEC filing
Reporting insiderSecurity / transactionAmount / priceValueTraded / disclosedSource
Global Chief Commercial OffCommon StockSale10b5-14,015$40.00 / share$160.6KSep 21Filed Sep 22 · 1d laterSEC filing
DirectorCommon StockSale10b5-15,000$40.95 / share$204.75KSep 14Filed Sep 16 · 2d laterSEC filing
Chief Scientific & Med OfficerCommon StockSale10b5-12 trades13,110avg $43.05 / share$564.41KSep 4Filed Sep 4 · 0d later
2 filings
  • 10,405 @ $42.89 · $446.3KSEC filing
  • 2,705 @ $43.66 · $118.11KSEC filing
Chief Financial OfficerCommon StockSale10b5-12 trades3,652avg $43.10 / share$157.39KSep 4Filed Sep 4 · 0d later
2 filings
  • 2,477 @ $42.81 · $106.03KSEC filing
  • 1,175 @ $43.71 · $51.36KSEC filing
EVP, General CounselCommon StockSale10b5-12 trades3,254avg $43.09 / share$140.21KSep 4Filed Sep 4 · 0d later
2 filings
  • 2,154 @ $42.79 · $92.17KSEC filing
  • 1,100 @ $43.67 · $48.04KSEC filing
DirectorCommon StockSale10b5-11,864$42.97 / share$80.1KSep 1Filed Sep 3 · 2d laterSEC filing
DirectorCommon StockSale10b5-12 trades3,729avg $52.89 / share$197.23KJun 18Filed Jun 22 · 4d later
2 filings
  • 3,200 @ $52.78 · $168.91KSEC filing
  • 529 @ $53.55 · $28.33KSEC filing
EVP, General CounselCommon StockSale10b5-12 trades3,176avg $49.76 / share$158.04KJun 4Filed Jun 4 · 0d later
2 filings
  • 1,400 @ $49.31 · $69.03KSEC filing
  • 1,776 @ $50.12 · $89.01KSEC filing
Chief Financial OfficerCommon StockSale10b5-12 trades3,561avg $49.73 / share$177.08KJun 4Filed Jun 4 · 0d later
2 filings
  • 1,600 @ $49.28 · $78.85KSEC filing
  • 1,961 @ $50.09 · $98.23KSEC filing
Chief Executive OfficerCommon StockSale10b5-1138,051$50.12 / share$6.92MJun 4Filed Jun 4 · 0d laterSEC filing
Global Chief Commercial OffCommon StockSale10b5-113,975$50.07 / share$699.73KJun 4Filed Jun 4 · 0d laterSEC filing
VP, Chief Accounting OfficerCommon StockSale24,000$45.40 / share$1.09MMay 22Filed May 27 · 5d laterSEC filing
DirectorCommon StockSale10b5-110,000$44.01 / share$440.13KMay 20Filed May 22 · 2d laterSEC filing
SVP, General CounselCommon StockSale10b5-15,102$38.05 / share$194.13KMay 6Filed May 8 · 2d laterSEC filing

Showing the latest 20 of 21 trades. Show all 21 trades

Explore furtherTechnical lab Company financials Test a strategy Compare company

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage
Source
SEC EDGAR · Form 4
Issuer CIK
0001384101
Latest public acceptance
Sep 22, 2026, 09:16 PM UTC
Score calculated
Oct 8, 2026, 03:54 PM UTC
Parser
form4-parser-1.5
Classifier
form4-classifier-1.1
Scoring methodology
insider-experimental-1.1
Availability
Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Congress transactions 3

All Congress filings
Purchase disclosed

Veracyte, Inc. - Common Stock (VCYT) · Stock

The filing reports a purchase for the member.

Gilbert Cisneros official portraitGilbert CisnerosReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
March 3, 2026
Filed April 7, 2026 · 35d laterOriginal report
Purchase disclosed

Veracyte, Inc. - Common Stock (VCYT) · Stock

The filing reports a purchase for the member.

Gilbert Cisneros official portraitGilbert CisnerosReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
February 18, 2026
Filed March 9, 2026 · 19d laterOriginal report
Partial sale disclosed

Veracyte, Inc. - Common Stock (VCYT) · Stock

The filing reports a partial sale for the member.

Gilbert Cisneros official portraitGilbert CisnerosReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
November 12, 2025
Filed December 15, 2025 · 33d laterOriginal report